

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**IVD Medical Holding Limited**  
**華檢醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1931)**

**CHANGE OF NON-EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of IVD Medical Holding Limited (the “**Company**”) announces that with effect from 8 March 2024: (1) Mr. Yang Zhaoxu (楊兆旭) resigned as a non-executive Director due to his retirement, and (2) Mr. Liu Fei (劉飛) has been appointed as a non-executive Director.

Mr. Yang has confirmed that he has no disagreement with the Board, and there are no matters that need to be brought to the attention of the holders of securities of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

A biography of Mr. Liu is set out below:

Mr. Liu Fei (劉飛), aged 37, has over a decade of working experience in research and development and in management. He joined Shinva Medical Instrument Co., Ltd. (山東新華醫療器械股份有限公司) (“**Shinva**”, a company whose shares are listed and traded on the Shanghai Stock Exchange (stock code: 600587), and a controlling shareholder of the Company under the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) in July 2009. He served in different positions in Shinva, including working in the infection control business department from July 2009 to September 2018, as the factory head of the Oral Technology Factory of Shinva from September 2018 to December 2023. Since December 2023, he has been the general manager of the in vitro diagnostics business department of Shinva, the chairman of the board of directors of Changchun Bioxun Biotech Co., Ltd. (長春博迅生物技術有限公司), the chairman of the board of directors and legal representative of Shandong Shinsun Biotechnology Co., Ltd. (山東新華普陽生物技術有限公司), and a director of Beijing Wotech Biological and Technological Co., Ltd. (北京威泰科生物技術有限公司).

Mr. Liu graduated from Qingdao University of Technology in China in June 2009, majoring in mechanical design, manufacturing and automation. He obtained the qualification of senior engineer in China in March 2021.

Mr. Liu will enter into a letter of appointment with the Company, under which he will hold office as a non-executive Director until the conclusion of the first annual general meeting of the Company following his appointment (and will then be subject to retirement and re-election), subject to termination by either party giving not less than three months' written notice to the other. His appointment is subject to the provisions of the articles of association of the Company with regard to vacation of office, removal and retirement by rotation of Directors. Mr. Liu is not expected to receive any remuneration from the Company for his office in the Company.

Mr. Liu has confirmed that, save as disclosed in this announcement, (i) he has no other relationship with any director, senior management, substantial or controlling shareholder of the Company as of the date of this announcement, (ii) he does not currently hold other position(s) within the Group; (iii) he has no interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and (iv) there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules in relation to his appointment. The Company is not aware of any other matters in relation to Mr. Liu's appointment that need to be brought to the attention of shareholders of the Company.

The Board would like to express its gratitude to Mr. Yang for his contributions to the Company, and welcome Mr. Liu to the Board.

By order of the Board  
**IVD Medical Holding Limited**  
**Ho Kuk Sing**  
*Chairman and Executive Director*

Hong Kong, 8 March 2024

*As at the date of this announcement (and following the change of composition of the Board mentioned in this announcement becoming effective), the Board comprises three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.*

*In this announcement, certain Chinese names of institutions, natural persons or other entities have been translated into English and included as unofficial translations for identification purposes only. In the event of any inconsistency, the Chinese names shall prevail.*